Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Unilever plc (UL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Unilever plc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.79 (market cap $4.49B), while Unilever plc trades at $62.07 (market cap $133.28B). The key difference: Unilever plc is far larger — about 29.7× ACADIA Pharmaceuticals Inc.'s market cap, and Unilever plc pays a 3.63% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | UL | |
|---|---|---|
Market Cap | $4.49B | $133.28B |
Sector | Health | Consumer Staples |
52-Week High | $28.06 | $74.59 |
52-Week Low | $20.06 | $55.05 |
Enterprise Value | $3.69B | $158.73B |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Unilever (UL) trades at $62.74, up 0.42% today, with a bullish technical signal from moving averages. Recent earnings misses contrast with strong profitability margins and a 53.32% ROE. The company is actively reshaping its portfolio through deals like the proposed McCormick food business combination and a $270 million innovation center investment, signaling strategic growth initiatives amid mixed quarterly performance.
UL presents a balanced risk-reward with fair valuation metrics, but faces execution risks from recent earnings shortfalls and portfolio transitions. The analyst community is divided, with a slim majority recommending Hold. Investors should weigh strong cash flow generation against competitive pressures in consumer goods markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
